Januvia (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin release and decrease glucagon secretion in a glucose‑dependent manner, helping to lower blood glucose.

The exact dose of Januvia is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycemic response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Januvia, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin, Januvia has a neutral effect on weight and a lower risk of gastrointestinal upset, but it is generally less potent as a first‑line agent. Compared with GLP‑1 receptor agonists, it is oral rather than injectable and has a different safety profile, lacking the nausea commonly seen with GLP‑1 agents.

Januvia tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Januvia is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber to maintain consistent dosing.

Patients should be alert for signs of pancreatitis such as severe, persistent abdominal pain, for severe allergic reactions including rash, swelling or difficulty breathing, and for unexplained joint pain. Any of these symptoms require immediate medical evaluation.

Januvia is contraindicated in individuals with a known hypersensitivity to sitagliptin or any of its excipients. It should also be avoided in patients with severe renal impairment unless dose adjustments are made, and in those with a history of pancreatitis until cleared by a physician.